Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm
07 Feb 2024
Phase 3Clinical Trial TerminationPhase 2
Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease, and it will not pursue future work on this therapy in blood cancers.
In an interim analysis, patients who received magrolimab had an increased risk of death compared to those who received standard care with AbbVie and Roche’s Venclexta and azacitidine. Gilead said Wednesday that the increased risk was “primarily driven by infections and respiratory failure.”
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.